Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 9;43(5):1491–1502. doi: 10.3892/or.2020.7537

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Cellular cytotoxicity of (17-AAG+Torin2)@MSNs-anti-VEGFR2 ab in vitro. (A) FRO cells were incubated with various concentrations of free drugs, and drugs loaded into either MSNs or MSNs-anti-VEGFR2 ab for 48 h. (B and C) FRO, and N-thy-ori 3-1 cell lines were incubated with control medium (Control), MSNs, (17-AAG+Torin2)@MSNs, (17-AAG+Torin2)@MSNs-Anti-VEGFR2 ab for 48 h (the concentration of 17-AAG or Torin2 was 1 µM, respectively). (D) Schematic illustration of the synthesis process of the (17-AAG+Torin2)@MSNs-anti-VEGFR2 ab. *P<0.05. 17-AAG, 17-allylamino-17-demethoxy-geldanamycin; Torin2 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; VEGFR2, vascular endothelial growth factor receptor 2.